Global Parkinson Disease Drug Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global Parkinson Disease Drug Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Sinemet-CR
  • 1.4.3 Trastal
  • 1.4.4 Madopar
  • 1.4.5 COMT Inhibitor
  • 1.4.6 Other
• 1.5 Market by Application
  • 1.5.1 Global Parkinson Disease Drug Market Share by Application (2014-2025)
  • 1.5.2 Under 40 Years Old
  • 1.5.3 40-65 Years Old
  • 1.5.4 Above 65 Years Old
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Parkinson Disease Drug Market Size
• 2.2 Parkinson Disease Drug Growth Trends by Regions
  • 2.2.1 Parkinson Disease Drug Market Size by Regions (2014-2025)
  • 2.2.2 Parkinson Disease Drug Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Opportunities

3 Market Share by Key Players

• 3.1 Parkinson Disease Drug Market Size by Manufacturers
  • 3.1.1 Global Parkinson Disease Drug Revenue by Manufacturers (2014-2019)
  • 3.1.2 Global Parkinson Disease Drug Revenue Market Share by Manufacturers (2014-2019)
  • 3.1.3 Global Parkinson Disease Drug Market Concentration Ratio (CR5 and HHI)
• 3.2 Parkinson Disease Drug Key Players Head office and Area Served
• 3.3 Key Players Parkinson Disease Drug Product/Solution/Service
• 3.4 Date of Enter into Parkinson Disease Drug Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global Parkinson Disease Drug Market Size by Type (2014-2019)
• 4.2 Global Parkinson Disease Drug Market Size by Application (2014-2019)

5 United States

• 5.1 United States Parkinson Disease Drug Market Size (2014-2019)
• 5.2 Parkinson Disease Drug Key Players in United States
• 5.3 United States Parkinson Disease Drug Market Size by Type
• 5.4 United States Parkinson Disease Drug Market Size by Application

6 Europe

• 6.1 Europe Parkinson Disease Drug Market Size (2014-2019)
• 6.2 Parkinson Disease Drug Key Players in Europe
• 6.3 Europe Parkinson Disease Drug Market Size by Type
• 6.4 Europe Parkinson Disease Drug Market Size by Application

7 China

• 7.1 China Parkinson Disease Drug Market Size (2014-2019)
• 7.2 Parkinson Disease Drug Key Players in China
• 7.3 China Parkinson Disease Drug Market Size by Type
• 7.4 China Parkinson Disease Drug Market Size by Application

8 Japan

• 8.1 Japan Parkinson Disease Drug Market Size (2014-2019)
• 8.2 Parkinson Disease Drug Key Players in Japan
• 8.3 Japan Parkinson Disease Drug Market Size by Type
• 8.4 Japan Parkinson Disease Drug Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia Parkinson Disease Drug Market Size (2014-2019)
• 9.2 Parkinson Disease Drug Key Players in Southeast Asia
• 9.3 Southeast Asia Parkinson Disease Drug Market Size by Type
• 9.4 Southeast Asia Parkinson Disease Drug Market Size by Application

10 India

• 10.1 India Parkinson Disease Drug Market Size (2014-2019)
• 10.2 Parkinson Disease Drug Key Players in India
• 10.3 India Parkinson Disease Drug Market Size by Type
• 10.4 India Parkinson Disease Drug Market Size by Application

11 Central & South America

• 11.1 Central & South America Parkinson Disease Drug Market Size (2014-2019)
• 11.2 Parkinson Disease Drug Key Players in Central & South America
• 11.3 Central & South America Parkinson Disease Drug Market Size by Type
• 11.4 Central & South America Parkinson Disease Drug Market Size by Application

12 International Players Profiles

• 12.1 Merck
  • 12.1.1 Merck Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 Parkinson Disease Drug Introduction
  • 12.1.4 Merck Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.1.5 Merck Recent Development
• 12.2 Akorn
  • 12.2.1 Akorn Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 Parkinson Disease Drug Introduction
  • 12.2.4 Akorn Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.2.5 Akorn Recent Development
• 12.3 GSK
  • 12.3.1 GSK Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 Parkinson Disease Drug Introduction
  • 12.3.4 GSK Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.3.5 GSK Recent Development
• 12.4 Novartis
  • 12.4.1 Novartis Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 Parkinson Disease Drug Introduction
  • 12.4.4 Novartis Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.4.5 Novartis Recent Development
• 12.5 Boehringer Ingelheim
  • 12.5.1 Boehringer Ingelheim Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 Parkinson Disease Drug Introduction
  • 12.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.5.5 Boehringer Ingelheim Recent Development
• 12.6 Teva Pharmaceutical
  • 12.6.1 Teva Pharmaceutical Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 Parkinson Disease Drug Introduction
  • 12.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.6.5 Teva Pharmaceutical Recent Development
• 12.7 Abbvie
  • 12.7.1 Abbvie Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 Parkinson Disease Drug Introduction
  • 12.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.7.5 Abbvie Recent Development
• 12.8 Kyowa Hakko Kirin Pharma
  • 12.8.1 Kyowa Hakko Kirin Pharma Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 Parkinson Disease Drug Introduction
  • 12.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.8.5 Kyowa Hakko Kirin Pharma Recent Development
• 12.9 Astellas Pharma
  • 12.9.1 Astellas Pharma Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 Parkinson Disease Drug Introduction
  • 12.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.9.5 Astellas Pharma Recent Development
• 12.10 Desitin Arzneimittel
  • 12.10.1 Desitin Arzneimittel Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 Parkinson Disease Drug Introduction
  • 12.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2014-2019)
  • 12.10.5 Desitin Arzneimittel Recent Development
• 12.11 Endo Pharmaceuticals
• 12.12 F.Hoffmann-La Roche
• 12.13 H.Lundbeck
• 12.14 Valeant
• 12.15 Apokyn
• 12.16 Orion
• 12.17 Stada Arzneimittel
• 12.18 US WorldMeds
• 12.19 Valeant Pharmaceuticals

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer